Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 73.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 280,547 shares of the biopharmaceutical company's stock after selling 763,826 shares during the period. AQR Capital Management LLC owned approximately 0.30% of Ultragenyx Pharmaceutical worth $11,803,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Invesco Ltd. grew its stake in shares of Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after acquiring an additional 25,487 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 5.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after acquiring an additional 81,667 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after acquiring an additional 653,088 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Ultragenyx Pharmaceutical by 27.9% during the fourth quarter. Marshall Wace LLP now owns 1,051,573 shares of the biopharmaceutical company's stock valued at $44,240,000 after acquiring an additional 229,561 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock traded down $0.82 during trading hours on Friday, hitting $35.16. 1,136,694 shares of the company were exchanged, compared to its average volume of 825,828. Ultragenyx Pharmaceutical Inc. has a one year low of $29.59 and a one year high of $60.37. The business's 50-day simple moving average is $36.77 and its two-hundred day simple moving average is $42.24. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -5.55 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same period in the prior year, the business earned ($2.03) EPS. The business's revenue was up 28.0% on a year-over-year basis. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares of the company's stock, valued at $4,289,227.60. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at $11,166,519.80. This represents a 2.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 125,405 shares of company stock valued at $5,285,169 over the last quarter. Insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

RARE has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Piper Sandler lowered their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Morgan Stanley raised their target price on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $90.93.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.